Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

Abstract Objective First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line set...

Full description

Bibliographic Details
Main Authors: Andrea Botticelli, Giulia Pomati, Alessio Cirillo, Giulia Mammone, Fabio Ciurluini, Bruna Cerbelli, Paolo Sciattella, Massimo Ralli, Umberto Romeo, Francesca De Felice, Carlo Catalano, Francesco Vullo, Marco Della Monaca, Sasan Amirhassankhani, Silverio Tomao, Valentino Valentini, Marco De Vincentiis, Vincenzo Tombolini, Carlo Della Rocca, Antonella Polimeni, Cira di Gioia, Alessandro Corsi, Giulia D’Amati, Silvia Mezi, Paolo Marchetti
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Journal of Translational Medicine
Subjects:
Head and neck cancer
Docetaxel
Cetuximab
Chemotherapy
First line
Frail patient population
Online Access:https://doi.org/10.1186/s12967-021-02975-3

Internet

https://doi.org/10.1186/s12967-021-02975-3

Similar Items